Reglitazar
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 170861-63-9
- Fòrmula: C22H20N2O5
- Peso molecular:392.40
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 3T3-L1 | EC50 |
1.1 x 10-7M
Compound: 2 (JTT-501)
|
Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
|
[PMID: 9599241] |
Chemical Information
-
No. CAS 170861-63-9
-
Peso molecular 392.40
-
Fòrmula C22H20N2O5
-
SMILES
O=C(C1CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)NOC1=O
-
Synonyms
JT 501
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Reglitazar Related Classifications
HY-101637 Related Classifications
Powered by Bioz